Salute e Benessere

Novo Nordisk A/S - share repurchase programme

Bagsværd , Denmark, 25September 2023– On 10 August 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023...
Nasdaq GlobeNewswire
25/09/2023

Intensity-modulated Radiotherapy Market worth $2.8 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=201922049 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=201922049 Browse in-depth TOC on "Intensity-modulated Radiotherapy Market" 145 - Tables 45 - Figures 257 - Pages Intensity-modulated Radiotherapy Market Scope: The breast cancer application segment accounted for a significant share of the Intensity-modulated radiotherapy...
PR Newswire
25/09/2023

Human Microbiome Market size worth USD 1,689.5 Million, Globally, by 2027 at…

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=24105 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=24105 Browse in-depth TOCon" Human Microbiome Market " 202 - Pages 126 – Tables 37 – Figures Advancements in Human Microbiome Research Fuel Global Market Growth The global Human Microbiome market is experiencing a remarkable surge, driven by a confluence of factors, including technological...
PR Newswire
25/09/2023

The Medical Waste Management Market Is Set To Reach A Value Of $21 Billion By…

Factors Driving Market Growth Several key factors contribute to this sustained growth in the globalmedical waste management market : Learn More On The Medical Waste Management Market Report –https://www.thebusinessresearchcompany.com/report/medical-waste-management-global-market-report Fragmented Market Landscape The medical waste management market exhibits fragmentation, with numerous small players operating worldwide. In 2022, the top ten competitors...
PR Newswire
25/09/2023

Skin Toner Market to reach US$ 2.1 billion by 2033 as Demand for Complete…

Due to millennials' growing preference for independent brands, European skin toner sales are expected to increase significantly. Indie brands are typically small-scale companies that offer specialized product lines, concentrate on innovations, and highly value authenticity. Due to millennials' growing preference for independent brands, European skin toner sales are expected to increase significantly. Indie brands are typically small-scale companies that offer specialized product lines,...
PR Newswire
25/09/2023

Pharming Group reports on results of the 2023 Extraordinary General Meeting of…

Leiden, The Netherlands, September 25, 2023:Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda.Shareholders approved the appointment of Dr. Richard Peters as Non-Executive director for a period of four years. As a result, Dr. Peters succeeds Mr. Paul Sekhri as Chair of the Board of Directors with immediate effect. Deborah Jorn, V...
Nasdaq GlobeNewswire
25/09/2023

PRADA SPRING/SUMMER 2024 WOMENSWEAR SHOW

**FACE** **FACE** Alexander starts by preparing the skin with Prada Skincare, employing Prada Augmented Skin The Serum as the first step. This is followed by Prada Augmented Skin The Cream, ensuring its complete absorption before the application of the base. The finishing touch is the delicate utilization of Prada Reveal Foundation, achieving a naturally diffused, soft-matte finish. To define the facial contours, Lynsey relies on Prada Monochrome soft matte lipsticks for contouring and...
PR Newswire
25/09/2023

The 88th CMEF in Shenzhen Set to Spotlight Advancements in the Medical Equipment…

Unveiling the Powerhouse: CMEF Showcasing the Thriving South China Market's Strengths, Advantages, and Unique Attributes Unveiling the Powerhouse: CMEF Showcasing the Thriving South China Market's Strengths, Advantages, and Unique Attributes The terminal market size ofChina'smedical equipment industry surged from308 billion yuanin 2015 to915.4 billion yuanin 2021, with a CAGR of 19.91%, driven by the expansion of medical insurance coverage, increasing medical visits, and the...
PR Newswire
25/09/2023

Daewoong Therapeutics Gets MFDS Nod for Phase 1 IND for the World's First…

DWRX2008 is an innovative nanoparticle eyedrop adaptation of Envlo®(enavogliflozin), which tackles the challenge of poor retinal drug absorption from oral use. It is thought to maintain the dosage efficiency of enavogliflozin, delivering therapeutic effects at just 1/30th the dose of leading SGLT2 inhibitors. Last April, DWRX2008 was granted Korea Drug Development Fund(KDDF) designation for advanced preclinical development. Notably, recent findings indicate its effectiveness in reducing central…
PR Newswire
25/09/2023

The Hurricane Gives Sports Regimen Advice for Men

Keep reading to find out more. Keep reading to find out more. The Hurricane: "It is necessary to establish a diet. Create a regime, eat at set times throughout the day, and diversify your diet so each meal contains proteins, fats and good carbohydrates. It is important not to snack so that insulin does not increase, which subsequently negatively affects your hormones. Be sure to drink enough water, from 2-3 litres, depending on your sports regimen." According to scientific…
PR Newswire
25/09/2023

Valo Health and Novo Nordisk to collaborate to discover and develop novel…

Collaboration will apply Valo's Opal Computational Platform™ and real-world patient dataset to enable the discovery and development of novel cardiometabolic drug programmes Novo Nordisk licenses three preclinical drug discovery programmes in cardiovascular diseases discovered and developed by Valo using the Opal Computational Platform™Valo will receive an upfront payment and a potential near-term milestone payment, totalling 60 million US dollars , and is...
Nasdaq GlobeNewswire
25/09/2023

Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for…

CompanyAnnouncement TEPKINLY ® (epcoritamab) is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory(R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapyConditional marketing authorization approval from the European Commission is supported by data from the pivotal phase 1/2 EPCORE™ NHL-1 clinical trial , which demonstrated 62 percent overall...
Nasdaq GlobeNewswire
25/09/2023

EQT Private Equity to sell LimaCorporate, one of the global leaders in joint…

EQT has supported LimaCorporate in the expansion of its product portfolio primarily through in-house innovation and the advancement of its 3D printing capabilities. It has invested to solidify its core offering and increase manufacturing capacity in the face of rapidly growing demand, while further developing talent to execute on the Company's market expansion, with accelerated global growth. In 2022, the Company reached revenues of EUR 249 million and it will continue to bring critical…
PR Newswire
25/09/2023

Zerion Pharma A/S elects Carl-Åke Carlsson as Chairman of the Board

ZERION's Dispersome® technology has proven to be very efficient in improving the solubility and bioavailability of small molecule drugs. ZERION has established partnerships with a significant number of large pharmaceutical companies that are exploiting the Dispersome® platform for both new chemical entities as well as currently marketed drugs. Some of these partnerships are now proceeding into the clinical phase. ZERION's Dispersome® technology has proven to be very efficient in improving the...
PR Newswire
25/09/2023

Industry Catapults Revolutionizing the Pharmaceutical Industry in Vietnam. Are…

Introduction With a population of over 98 Mn and a growing affluent class,Vietnam'sexpenditure on medicines has risen significantly, showcasing its high paying capacity for healthcare. The country's aging population further contributes to the demand for pharmaceutical drugs. To address these needs, the Vietnamese government has implemented healthcare reforms and initiatives to boost domestic pharmaceutical production. Specialty drugs are sought after to combat the increasing...
PR Newswire
25/09/2023

"Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery"

Guided by platform-based corporate strategy "Innovation + Internationalization", Kexing Biopharm has formulated R&D plans emphasizing "Molecule Generation", "NMPA/FDA dual IND Filing" and "Out-licensing". The goal is to develop innovative medicines that address unmet medical needs, and build cutting-edge technology platforms. Supported by its well-established technologies for creating novel protein and antibody-based biologics, the Company's…
PR Newswire
25/09/2023

EQT PRIVATE EQUITY TO SELL LIMACORPORATE TO ENOVIS: THE ITALIAN SITE IN SAN…

LimaCorporate, together with EQT, has been investing to solidify its core offering and increase manufacturing capacity in the face of rapidly growing demand, while further developing talent to execute the market expansion, with accelerated global growth. In 2022, the company reached revenues of EUR 249 million and it will continue to bring critical innovation to surgeons and patients as part of Enovis. LimaCorporate, together with EQT, has been investing to solidify its core offering and...
PR Newswire
25/09/2023

EPKINLYTM (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare…

Media Release Subcutaneous EPKINLY TM (epcoritamab) is the first and only bispecific antibody approved in Japan to treat adult patients with certain types of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after two or more lines of systemic therapyApproval based on results of EPCORE TMNHL-3 and EPCORE TMNHL-1 clinical trials, evaluating EPKINLYin patients with certain types of R/RLBCLLBCLis a common form of non-Hodgkin's lymphoma (NHL)...
Nasdaq GlobeNewswire
25/09/2023

MAR Weekly Report_VIRBAC SA_18 to 22 September 2023

Statement of transactions in own shares from September 18, 2023 to September 22, 2023BNP PARIBAS EXANE Aggregated presentation by day and by market Submission period18 to 22 SEP 2023 Submission Date22-Sep-2023 Issuer nameISIN CodeTransaction dateDaily total volume (in number of shares)Daily weighted average price...
Nasdaq GlobeNewswire
25/09/2023

Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to…

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its commercialization partner in Japan, Fuji Pharma Co., Ltd. (“Fuji”), has received marketing approval for AVT04 (ustekinumab), a biosimilar to Stelara®, from the Japanese Ministry of Health, Labor and Welfare. Based on publicly available information, AVT04 is the first biosimilar to Stelara to be approved for sale in global...
Nasdaq GlobeNewswire
25/09/2023

SciBase initiates pilot with Bare Dermatology to advance skin cancer detection…

"We are excited to together with Bare Dermatology support their efforts to provide the highest quality care to their patients through the use of Nevisense, the only FDA approved melanoma detection technology at point-of-care. SciBase is focused on addressing the need for early melanoma detection in the highest at-risk patient population in the U.S. We are expanding in the areas where melanoma rates are high and where patients have access to the Nevisense test fee schedule from Medical…
PR Newswire
25/09/2023

Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration…

Under the terms of the agreement, Vernalis will use its expertise to enable drug discovery against an undisclosed portfolio of targets and use fragment and structure-based methods to identify small molecules that modulate their activity. This research will be combined with the oncology experience of Pierre Fabre Laboratories to identify drug candidates for treatment of a range of cancers for further development and commercialisation by Pierre Fabre Laboratories. The research at Vernalis...
PR Newswire
25/09/2023

Press Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor…

Once-weekly ALTUVIIIO ®approved in Japan asa new class of factor VIII therapy for hemophilia AALTUVIIIO is a first-in-class, high-sustained factor VIII replacement therapy which provides highly effective bleed protection in adults and children with hemophilia AApproval demonstrates commitment to delivering innovation and a paradigm shift in the hemophilia treatment landscapeParis , September25 , 2023. The Japanese Ministry of Health, Labor, and Welfare...
Nasdaq GlobeNewswire
25/09/2023

'LEQEMBI® Intravenous Infusion' approved for the treatment of Alzheimer's…

"The approval of LEQEMBI in Japan is another important step in the fight against Alzheimer's disease," said Gunilla Osswald, CEO of BioArctic. "I am impressed by the diligent efforts of our partner Eisai to ensure that this important innovation can reach patients around the globe, and I am looking forward to more approvals in the year to come to give patients and doctors worldwide the opportunity of this new treatment." "The approval of LEQEMBI inJapanis another…
PR Newswire
25/09/2023
Altri  Comunicati